Works matching AU Lonial, Sagar

Results: 211
    1
    2
    3

    Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth.

    Published in:
    Science Signaling, 2009, v. 2, n. 97, p. 1, doi. 10.1126/scisignal.2000431
    By:
    • Hitosugi, Taro;
    • Kang, Sumin;
    • Vander Heiden, Matthew G.;
    • Chung, Tae-Wook;
    • Elf, Shannon;
    • Lythgoe, Katherine;
    • Dong, Shaozhong;
    • Lonial, Sagar;
    • Xu Wang;
    • Chen, Georgia Z.;
    • Xie, Jianxin;
    • Gu, Ting-Lei;
    • Polakiewicz, Roberto D.;
    • Roesel, Johannes L.;
    • Boggon, Titus J.;
    • Khuri, Fadlo R.;
    • Gilliland, D. Gary;
    • Cantley, Lewis C.;
    • Kaufman, Jonathan;
    • Chen, Jing
    Publication type:
    Article
    4
    5

    Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.

    Published in:
    2020
    By:
    • Harvey, R. Donald;
    • Carthon, Bradley C.;
    • Lewis, Colleen;
    • Hossain, Mohammad S.;
    • Zhang, Chao;
    • Chen, Zhengjia;
    • Harris, Wayne B.;
    • Alese, Olatunji B.;
    • Shaib, Walid;
    • Bilen, Mehmet A.;
    • Lawson, David H.;
    • Wu, Christina;
    • Steuer, Conor E.;
    • El-Rayes, Bassel F.;
    • Khuri, Fadlo R.;
    • Lonial, Sagar;
    • Waller, Edmund K.;
    • Ramalingam, Suresh S.;
    • Owonikoko, Taofeek K.
    Publication type:
    journal article
    6
    7
    8
    9
    10

    A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00768-5
    By:
    • Chng, Wee-Joo;
    • Lonial, Sagar;
    • Morgan, Gareth J.;
    • Iida, Shinsuke;
    • Moreau, Philippe;
    • Kumar, Shaji K.;
    • Twumasi-Ankrah, Philip;
    • Villarreal, Miguel;
    • Dash, Ajeeta B.;
    • Vorog, Alexander;
    • Zhang, Xiaoquan;
    • Suryanarayan, Kaveri;
    • Labotka, Richard;
    • Dimopoulos, Meletios A.;
    • Rajkumar, S. Vincent
    Publication type:
    Article
    11
    12

    Venetoclax ex vivo functional profiling predicts improved progression-free survival.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 8, p. 1, doi. 10.1038/s41408-022-00710-9
    By:
    • Gupta, Vikas A.;
    • Matulis, Shannon M.;
    • Barwick, Benjamin G.;
    • Bog, R. Devin;
    • Shebelut, Conrad W.;
    • Shanmugam, Mala;
    • Neri, Paola;
    • Bahlis, Nizar J.;
    • Dhodapkar, Madhav V.;
    • Heffner, Leonard T.;
    • Hofmeister, Craig C.;
    • Joseph, Nisha S.;
    • Lonial, Sagar;
    • Kaufman, Jonathan L.;
    • Jaye, David L.;
    • Nooka, Ajay K.;
    • Boise, Lawrence H.
    Publication type:
    Article
    13

    Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).

    Published in:
    Blood Cancer Journal, 2021, v. 11, n. 5, p. 1, doi. 10.1038/s41408-021-00494-4
    By:
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Thulasi, Praneetha;
    • Badros, Ashraf Z.;
    • Jeng, Bennie H.;
    • Callander, Natalie S.;
    • Potter, Heather A.;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Popat, Rakesh;
    • Degli Esposti, Simona;
    • Byrne, Julie;
    • Opalinska, Joanna;
    • Baron, January;
    • Piontek, Trisha;
    • Gupta, Ira;
    • Dana, Reza;
    • Farooq, Asim V.;
    • Colby, Kathryn;
    • Jakubowiak, Andrzej
    Publication type:
    Article
    14
    15

    Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 10, p. 1, doi. 10.1038/s41408-020-00369-0
    By:
    • Richardson, Paul G.;
    • Lee, Hans C.;
    • Abdallah, Al-Ola;
    • Cohen, Adam D.;
    • Kapoor, Prashant;
    • Voorhees, Peter M.;
    • Hoos, Axel;
    • Wang, Karrie;
    • Baron, January;
    • Piontek, Trisha;
    • Byrne, Julie;
    • Richmond, Scott;
    • Jewell, Roxanne C.;
    • Opalinska, Joanna;
    • Gupta, Ira;
    • Lonial, Sagar
    Publication type:
    Article
    16

    Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41408-020-00357-4
    By:
    • Dimopoulos, Meletios A.;
    • Lonial, Sagar;
    • White, Darrell;
    • Moreau, Philippe;
    • Weisel, Katja;
    • San-Miguel, Jesus;
    • Shpilberg, Ofer;
    • Grosicki, Sebastian;
    • Špička, Ivan;
    • Walter-Croneck, Adam;
    • Magen, Hila;
    • Mateos, Maria-Victoria;
    • Belch, Andrew;
    • Reece, Donna;
    • Beksac, Meral;
    • Spencer, Andrew;
    • Oakervee, Heather;
    • Orlowski, Robert Z.;
    • Taniwaki, Masafumi;
    • Röllig, Christoph
    Publication type:
    Article
    17

    Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.

    Published in:
    2020
    By:
    • Mina, Roberto;
    • Joseph, Nisha S.;
    • Gay, Francesca;
    • Kastritis, Efstathios;
    • Petrucci, Maria Teresa;
    • Kaufman, Jonathan L.;
    • Montefusco, Vittorio;
    • Gavriatopoulou, Maria;
    • Patriarca, Francesca;
    • Omedé, Paola;
    • Boise, Lawrence H.;
    • Roussou, Maria;
    • Giuliani, Nicola;
    • Oliva, Stefania;
    • Offidani, Massimo;
    • Belotti, Angelo;
    • Jaye, David L.;
    • De Paoli, Lorenzo;
    • Terpos, Evangelos;
    • Lonial, Sagar
    Publication type:
    Letter
    18

    Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.

    Published in:
    Blood Cancer Journal, 2019, v. 9, n. 12, p. 1, doi. 10.1038/s41408-019-0254-0
    By:
    • Schmidt, Timothy M.;
    • Barwick, Benjamin G.;
    • Joseph, Nisha;
    • Heffner, Leonard T.;
    • Hofmeister, Craig C.;
    • Bernal, Leon;
    • Dhodapkar, Madhav V.;
    • Gupta, Vikas A.;
    • Jaye, David L.;
    • Wu, Jiayi;
    • Goyal, Subir;
    • Chen, Zhengjia;
    • Boise, Lawrence H.;
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Kaufman, Jonathan L.
    Publication type:
    Article
    19

    Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.

    Published in:
    2020
    By:
    • Farooq, Asim V.;
    • Degli Esposti, Simona;
    • Popat, Rakesh;
    • Thulasi, Praneetha;
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Jakubowiak, Andrzej;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Badros, Ashraf Z.;
    • Jeng, Bennie H.;
    • Callander, Natalie S.;
    • Opalinska, Joanna;
    • Baron, January;
    • Piontek, Trisha;
    • Byrne, Julie;
    • Gupta, Ira;
    • Colby, Kathryn
    Publication type:
    Correction Notice
    20

    Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.

    Published in:
    Ophthalmology & Therapy, 2020, v. 9, n. 4, p. 889, doi. 10.1007/s40123-020-00280-8
    By:
    • Farooq, Asim V.;
    • Degli Esposti, Simona;
    • Popat, Rakesh;
    • Thulasi, Praneetha;
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Jakubowiak, Andrzej;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Badros, Ashraf Z.;
    • Jeng, Bennie H.;
    • Callander, Natalie S.;
    • Opalinska, Joanna;
    • Baron, January;
    • Piontek, Trisha;
    • Byrne, Julie;
    • Gupta, Ira;
    • Colby, Kathryn
    Publication type:
    Article
    21
    22

    Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 2, p. 383, doi. 10.3109/10428194.2014.921296
    By:
    • Nastoupil, Loretta J.;
    • Shenoy, Pareen J.;
    • Ambinder, Alex;
    • Koff, Jean L.;
    • Nooka, Ajay K.;
    • Waller, Edmund K.;
    • Langston, Amelia;
    • Seward, Miray;
    • Kaufman, Jonathan L.;
    • Bernal-Mizrachi, Leon;
    • King, Nassoma;
    • Lechowicz, Mary Jo;
    • Lonial, Sagar;
    • Sinha, Rajni;
    • Flowers, Christopher R.
    Publication type:
    Article
    23
    24

    Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

    Published in:
    American Journal of Hematology, 2016, v. 91, n. 6, p. 575, doi. 10.1002/ajh.24351
    By:
    • Jurczyszyn, Artur;
    • Grzasko, Norbert;
    • Gozzetti, Alessandro;
    • Czepiel, Jacek;
    • Cerase, Alfonso;
    • Hungria, Vania;
    • Crusoe, Edvan;
    • Silva Dias, Ana Luiza Miranda;
    • Vij, Ravi;
    • Fiala, Mark A.;
    • Caers, Jo;
    • Rasche, Leo;
    • Nooka, Ajay K.;
    • Lonial, Sagar;
    • Vesole, David H.;
    • Philip, Sandhya;
    • Gangatharan, Shane;
    • Druzd-Sitek, Agnieszka;
    • Walewski, Jan;
    • Corso, Alessandro
    Publication type:
    Article
    25
    26
    27
    28

    Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01120-9
    By:
    • Joseph, Nisha S.;
    • Kaufman, Jonathan L.;
    • Gupta, Vilas A.;
    • Hofmeister, Craig C.;
    • Dhodapkar, Madhav V.;
    • Boise, Lawrence H.;
    • DiCamillo, Sara M.;
    • Roberts, Danielle;
    • Nooka, Ajay K.;
    • Lonial, Sagar
    Publication type:
    Article
    29
    30
    31
    32

    P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
    By:
    • Lonial, Sagar;
    • Berdeja, Jesus G.;
    • Dimopoulos, Meletios-Athanasios;
    • Jagannath, Sundar;
    • Knop, Stefan;
    • Hang Quach;
    • Rodríguez-Otero, Paula;
    • Richardson, Paul G.;
    • Sorrell, April;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • Tuong Vi Nguyen;
    • Hong, Kevin;
    • Peluso, Teresa;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    33

    P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S149, doi. 10.1016/S2152-2650(21)02329-6
    By:
    • Lonial, Sagar;
    • Nooka, Ajay;
    • Thulasi, Praneetha;
    • Badros, Ashraf Z.;
    • Jeng, Bennie;
    • Callander, Natalie S.;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Popat, Rakesh;
    • Esposti, Simona Degli;
    • Baron, January;
    • Doherty, Allison;
    • Lewis, Eric;
    • Opalinska, Joanna;
    • Prani Paka;
    • Piontek, Trisha;
    • Gupta, Ira;
    • Farooq, Asim V.;
    • Jakubowiak, Andrzej
    Publication type:
    Article
    34
    35
    36

    OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02101-7
    By:
    • Anderson, Jr., Larry D.;
    • Nina Shah;
    • Jagannath, Sundar;
    • Berdeja, Jesus G.;
    • Lonial, Sagar;
    • Raje, Noopur;
    • Siegel, David S.;
    • Yi Lin;
    • Moreau, Philippe;
    • Yakoub-Agha, Ibrahim;
    • Delforge, Michel;
    • Einsele, Hermann;
    • Goldschmidt, Hartmut;
    • Weisel, Katja;
    • Cavo, Michele;
    • Reece, Donna E.;
    • Rambaldi, Alessandro;
    • Truppel-Hartmann, Anna;
    • Patel, Payal;
    • Liping Huang
    Publication type:
    Article
    37

    OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
    By:
    • Lonial, Sagar;
    • Richardson, Paul G.;
    • Popat, Rakesh;
    • Stadtmauer, Edward A.;
    • Larsen, Jeremy T.;
    • Oriol, A.;
    • Knop, Stefan;
    • Jagannath, Sundar;
    • Cook, Gordon;
    • Badros, Ashraf Z.;
    • Rodríguez-Otero, Paula;
    • Siegel, David S.;
    • Tuong Vi Nguyen;
    • Micco, Antonia Di;
    • Amin, Alpesh;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    38
    39

    MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S419, doi. 10.1016/S2152-2650(21)01940-6
    By:
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Thulasi, Praneetha;
    • Badros, Ashraf Z.;
    • Jeng, Bennie H.;
    • Callander, Natalie S.;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Popat, Rakesh;
    • Esposti, Simona Degli;
    • Baron, January;
    • Doherty, Allison;
    • Lewis, Eric;
    • Opalinska, Joanna;
    • Paka, Prani;
    • Piontek, Trisha;
    • Gupta, Ira;
    • Farooq, Asim V.;
    • Jakubowiak, Andrzej
    Publication type:
    Article
    40

    ABCL-378: Prolonged Cytopenias in Autologous Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S396, doi. 10.1016/S2152-2650(21)01898-X
    By:
    • Santapuram, Pranav;
    • Rupji, Manali;
    • Graiser, Michael;
    • Waller, Edmund;
    • Blum, Kristie;
    • Allen, Pamela;
    • Koff, Jean;
    • Heffner, Leonard;
    • Lechowicz, Mary;
    • Lonial, Sagar;
    • Kaufman, Jonathan;
    • Dhopadkar, Madhav;
    • Nooka, Ajay;
    • Blum, William;
    • Klisovic, Rebecca;
    • Joseph, Nisha;
    • Gupta, Vikas;
    • Langston, Amelia;
    • Cohen, Jonathan
    Publication type:
    Article
    41

    Poster: MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥ 12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01576-7
    By:
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Thulasi, Praneetha;
    • Badros, Ashraf Z.;
    • Jeng, Bennie H.;
    • Callander, Natalie S.;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Popat, Rakesh;
    • Esposti, Simona Degli;
    • Baron, January;
    • Doherty, Allison;
    • Lewis, Eric;
    • Opalinska, Joanna;
    • Paka, Prani;
    • Piontek, Trisha;
    • Gupta, Ira;
    • Farooq, Asim V.;
    • Jakubowiak, Andrzej
    Publication type:
    Article
    42

    Poster: ABCL-378: Prolonged Cytopenias in Autologous Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S240, doi. 10.1016/S2152-2650(21)01509-3
    By:
    • Santapuram, Pranav;
    • Rupji, Manali;
    • Graiser, Michael;
    • Waller, Edmund;
    • Blum, Kristie;
    • Allen, Pamela;
    • Koff, Jean;
    • Heffner, Leonard;
    • Lechowicz, Mary;
    • Lonial, Sagar;
    • Kaufman, Jonathan;
    • Dhopadkar, Madhav;
    • Nooka, Ajay;
    • Blum, William;
    • Klisovic, Rebecca;
    • Joseph, Nisha;
    • Gupta, Vikas;
    • Langston, Amelia;
    • Cohen, Jonathan
    Publication type:
    Article
    43
    44
    45
    46

    Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e243, doi. 10.1016/j.clml.2019.09.404
    By:
    • Bernal, Leon;
    • Nooka, Ajay;
    • Cole, Craig;
    • Heffner, Leonard T.;
    • Ye, Jing Christine;
    • Vij, Ravi;
    • Chen, Zhengjia;
    • Zhang, Chao;
    • Rushton, John;
    • Munevver, Cinnar;
    • Lonial, Sagar;
    • Kaufman, Jonathan L.
    Publication type:
    Article
    47

    Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e118, doi. 10.1016/j.clml.2019.09.196
    By:
    • Vogl, Dan T.;
    • Nooka, Ajay;
    • Gavriatopoulou, Maria;
    • Yee, Andrew;
    • Huff, Carol;
    • Moreau, Philippe;
    • Dingli, David;
    • Cole, Craig;
    • Richardson, Paul G.;
    • Dimopoulos, Meletios A.;
    • Lonial, Sagar;
    • Stewart, Keith;
    • Chari, Ajai;
    • Richter, Joshua;
    • Biran, Noa;
    • Siegel, David S.;
    • Liu, Jianjun;
    • Joshi, Anita;
    • Shah, Jatin;
    • Shacham, Sharon
    Publication type:
    Article
    48

    Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e117, doi. 10.1016/j.clml.2019.09.195
    By:
    • Gavriatopoulou, Maria;
    • Vogl, Dan T.;
    • Nooka, Ajay;
    • Dingli, David;
    • Cole, Craig;
    • Moreau, Philippe;
    • Huff, Carol;
    • Yee, Andrew;
    • Dimopoulos, Meletios A.;
    • Lonial, Sagar;
    • Richardson, Paul G.;
    • Stewart, Keith;
    • Chari, Ajai;
    • Richter, Joshua;
    • Biran, Noa;
    • Siegel, David S.;
    • Liu, Jianjun;
    • Joshi, Anita;
    • Shah, Jatin;
    • Shacham, Sharon
    Publication type:
    Article
    49
    50